The metabolism of orally administered L-Dopa in Parkinsonism.
1. Gas-liquid chromatographic methods were used to measure urinary acidic and alcoholic metabolites of L-DOPA, which had been administered in high oral dosage to patients with postencephalitic and idiopathic Parkinsonism.2. The output of these compounds was normal before treatment. During drug therapy, large quantities of the dopamine metabolites, homovanillic acid and dihydroxyphenylacetic acid, were excreted but traces only of 4-hydroxy-3-methoxyphenylethanol. Noradrenaline metabolites showed little change in output other than a small increase in 4-hydroxy-3-methoxymandelic acid.3. Information was obtained about a number of minor routes of degradation which might be implicated in the therapeutic action of L-DOPA. A raised output of m-hydroxyphenylacetic acid pointed to p-dehydroxylation of dihydroxyphenylacetic acid by gut flora. Evidence of transamination as a minor metabolic pathway was obtained by finding appreciable urinary levels of 4-hydroxy-3-methoxyphenyllactic acid. A keto-acid precursor of this compound may act as competitive inhibitor of an enzyme active in the normal degradation route of tyrosine, p-hydroxyphenylpyruvic acid oxidase, for increased amounts of p-hydroxyphenyllactic acid, the major metabolic derivative of p-hydroxyphenylpyruvic acid, accumulated in the urine during DOPA treatment.
D002849:Chromatography, Gas; D004295:Dihydroxyphenylalanine / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism*; D010648:Phenylacetates / Q000652:urine; D010667:Phenylpyruvic Acids / Q000378:metabolism; D014642:Vanilmandelic Acid / Q000652:urine
D010648:Phenylacetates; D010667:Phenylpyruvic Acids; D014642:Vanilmandelic Acid; D004295:Dihydroxyphenylalanine; D009638:Norepinephrine